Brokerages Set T2 Biosystems Inc (NASDAQ:TTOO) Target Price at $4.07

Shares of T2 Biosystems Inc (NASDAQ:TTOO) have earned an average recommendation of “Hold” from the ten brokerages that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $4.07.

Several research analysts have recently issued reports on TTOO shares. Janney Montgomery Scott raised T2 Biosystems from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a research note on Thursday, September 12th. ValuEngine raised T2 Biosystems from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Leerink Swann set a $5.00 target price on T2 Biosystems and gave the company a “buy” rating in a research note on Thursday, September 12th. Svb Leerink raised their target price on T2 Biosystems from $3.00 to $5.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Finally, Zacks Investment Research raised T2 Biosystems from a “sell” rating to a “hold” rating in a research note on Friday.

A number of hedge funds have recently made changes to their positions in the stock. Cable Hill Partners LLC boosted its stake in T2 Biosystems by 45.0% during the third quarter. Cable Hill Partners LLC now owns 29,000 shares of the medical equipment provider’s stock valued at $73,000 after buying an additional 9,000 shares in the last quarter. Focused Wealth Management Inc boosted its stake in T2 Biosystems by 32.7% during the third quarter. Focused Wealth Management Inc now owns 40,550 shares of the medical equipment provider’s stock valued at $101,000 after buying an additional 10,000 shares in the last quarter. Founders Capital Management lifted its holdings in shares of T2 Biosystems by 183.3% during the third quarter. Founders Capital Management now owns 17,000 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 11,000 shares during the last quarter. Ironwood Financial llc lifted its holdings in shares of T2 Biosystems by 202.8% during the third quarter. Ironwood Financial llc now owns 18,268 shares of the medical equipment provider’s stock valued at $46,000 after purchasing an additional 12,234 shares during the last quarter. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of T2 Biosystems during the third quarter valued at $32,000. 39.05% of the stock is owned by institutional investors and hedge funds.

Shares of TTOO traded up $0.25 during trading on Thursday, reaching $1.76. The company’s stock had a trading volume of 1,051,400 shares, compared to its average volume of 547,969. T2 Biosystems has a twelve month low of $0.52 and a twelve month high of $5.38. The company has a market cap of $67.25 million, a price-to-earnings ratio of -1.40 and a beta of 1.23. The company has a fifty day moving average of $2.49 and a two-hundred day moving average of $1.96.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.

Featured Article: How is diluted EPS different from basic EPS?

Analyst Recommendations for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.